Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acetaminophen + dextromethorphan + phenylephrine (Farabi Pharmaceutical)
- Development stage
- Phase 1
- Lead developer
- Farabi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Faracold is an oral combination tablet developed by Farabi Pharmaceutical Company for the symptomatic relief of the common cold and influenza in adults. It contains three active ingredients: acetaminophen (an analgesic and antipyretic), dextromethorphan hydrobromide (a cough suppressant), and phenylephrine hydrochloride (a nasal decongestant). Acetaminophen acts primarily by inhibiting prostaglandin synthesis in the central nervous system to reduce fever and pain. Dextromethorphan acts centrally on the cough center in the medulla to suppress non-productive coughs. Phenylephrine is a selective alpha-1 adrenergic receptor agonist that induces vasoconstriction in the nasal mucosa, thereby reducing nasal congestion and sinus pressure.
- Brand names
- Faracold
- Other names
- acetaminophen + dextromethorphan hydrobromide + phenylephrine hydrochlorideacetaminophen/dextromethorphan/phenylephrineparacetamol + dextromethorphan + phenylephrine
02
Targets
AMPAR (AMPA receptor)ADRA1A (α1A)ADRA1B (α1B)ADRA1D (α1D)Nicotinic Acetylcholine ReceptorNET (Norepinephrine Transporter)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)SERT (Sodium-dependent serotonin transporter)SIGMAR1 (Sigma non-opioid intracellular receptor 1)CaV (Voltage-gated calcium channel protein complex)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on acetaminophen + dextromethorphan + phenylephrine (Farabi Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acetaminophen + dextromethorphan + phenylephrine (Farabi Pharmaceutical).